Recently, Chongqing Claruvis Pharmaceutical Co., Ltd. ("Claruvis") announced that Retoxin®, an innovative recombinant botulinum toxin type A injection for the improvement of moderate-to-severe glabellar lines in adults, received marketing approval from the Chinese National Medical Products Administration (NMPA). Retoxin® is the first such product developed with independent intellectual property rights. Tigermed-Jyton provided clinical operation services for the registrational clinical trial supporting this approval.
(Image source: NMPA official website)
Traditional botulinum toxin is extracted from Clostridium botulinum, a process that is complex, batch-to-batch variable, and poses potential biosafety risks. As the first recombinant botulinum toxin type A product independently developed by Claruvis, Retoxin® eliminates these biosafety concerns while preserving protein activity. Its innovative manufacturing process yields a recombinant toxin characterized by high purity, high specific activity, and low immunogenicity.
Tigermed-Jyton’s medical aesthetics team has over ten years of extensive experience in the industry. Leveraging more than 60 research centers and over 100 investigators, the team has completed more than 140 medical aesthetics studies, building a substantial project portfolio. These projects cover mainstream products including hyaluronic acid fillers, botulinum toxins, lasers, and energy-based devices.
The team has gained extensive experience in facial wrinkle correction, contour improvement, pigmented lesion treatment, and skin rejuvenation. Tigermed-Jyton has supported the market approval of many milestone products, including:
The first CaHA filler in China
The first Class III ultrasonic device in China
The world’s first pigmentation correction needle
The world’s first Class III radiofrequency cosmetic device
The world’s first Class III hydrogel-based filler
The world’s first medical-grade Type I collagen implant derived from bovine Achilles tendon
These achievements fully demonstrate Tigermed-Jyton’s leadership in medical aesthetics innovation. Tigermed-Jyton provides professional, compliant, and efficient integrated clinical research solutions for medical aesthetic products, helping to bring high-quality products to market.
About Claruvis
Claruvis is an innovation-driven biopharmaceutical company controlled by MingMed Biotechnology Co., Ltd., focusing on the R&D, production and commercialization of botulinum toxins along recombinant technology routes. The company has assembled a core team with cutting-edge scientific vision and industrialization capabilities, bringing together internationally outstanding basic research experts in botulinum toxins and experienced senior high-level students in the beauty and middle school. Based on its own R&D platform for serial recombinant protein drugs, Claruvis has successfully developed the world's first recombinant botulinum toxin type A, achieving technological breakthroughs in this field from natural extraction to precise genetic recombination. With its excellent operating ability and global competitiveness, the company will continue to deepen its recombinant botulinum toxin field, promote root innovation and transform efficiently, and continuously develop safer and better innovative drugs to benefit patients worldwide.
Obtain the latest industry and regulatory updates on a monthly basis.
Tel：+86-400-0739-391
Email：consult@tigermedgrp.com
Add：Suite 808, Union Plaza, Chaowai Street, Chaoyang District, Beijing
China Postal Code：100020